Martine Rothblatt Files Form 144 for UTHR: 4,000 Shares Proposed Sale

Rhea-AI Filing Summary

UNITED THERAPEUTICS (UTHR) Form 144 notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC on 09/17/2025, with an aggregate market value of $1,600,686.85. The securities were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired on that date and paid via vested options settled in common shares. The filing lists the company’s outstanding shares as 45,230,000.

The notice also discloses six sales by Martine Rothblatt during 09/09–09/16/2025 totaling 28,000 shares with gross proceeds shown for each sale. The filer represents they are not aware of undisclosed material adverse information and certifies compliance with Rule 144 procedures.

Positive

• Full Rule 144 disclosure filed with broker, trade dates, share counts, and gross proceeds for recent sales
• Source of shares disclosed as executive deferred compensation and exercise of vested options (acquisition date 03/15/2016)
• Amounts and broker identified (TD Securities (USA) LLC) facilitating traceability of transactions

Negative

• Insider selling activity includes 28,000 shares sold in the past week, which is disclosed but represents ongoing insider sales
• Filing lacks contextual details such as intent for proceeds or any trading plan adoption date (no 10b5-1 plan date provided)

Insights

Securities Analyst

TL;DR Insider sale disclosure of modest size relative to outstanding shares; sourced from deferred compensation.

The Form 144 shows a proposed sale of 4,000 common shares and prior sales totaling 28,000 shares by Martine Rothblatt, executed through TD Securities. The shares to be sold were acquired in 2016 under an executive deferred compensation arrangement and settled via vested options. With 45,230,000 shares outstanding, the proposed 4,000-share sale represents approximately 0.009% of the outstanding stock and the recent 28,000-share activity represents approximately 0.062%. The filing provides transaction dates, broker, and gross proceeds for prior sales and includes the standard representation regarding material nonpublic information.

Corporate Governance Expert

TL;DR Proper insider sale disclosure filed; documentation identifies source as executive deferred compensation.

The notice documents compliance with Rule 144 filing requirements, naming the broker, trade dates, and amounts. It states the acquisition source as executive deferred compensation from Martine Rothblatt and indicates payment via exercised vested options. The filing includes the mandatory attestation about material information. No additional governance actions or plan adoption details are provided in the content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1600686.85	45230000	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the UTHR Form 144 disclose about proposed sales?

The notice discloses a proposed sale of 4,000 common shares on 09/17/2025 via TD Securities with an aggregate market value of $1,600,686.85.

Who is the seller in the UTHR Form 144 filing?

The seller is Martine Rothblatt, and the shares were originally acquired on 03/15/2016 as executive deferred compensation.

How many UTHR shares were outstanding according to the filing?

The filing reports 45,230,000 shares outstanding.

What recent insider sales are disclosed in the Form 144?

The filing lists six sales from 09/09/2025 to 09/16/2025 totaling 28,000 shares with gross proceeds provided for each sale.

Through which broker are the proposed sales to be executed?

The proposed sale is to be executed through TD Securities (USA) LLC, 125 Park Ave, New York.